Haemonetics Co. (NYSE:HAE) Shares Acquired by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD increased its stake in Haemonetics Co. (NYSE:HAE - Free Report) by 7.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 354,281 shares of the medical instruments supplier's stock after buying an additional 25,617 shares during the period. Price T Rowe Associates Inc. MD owned about 0.71% of Haemonetics worth $27,664,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in HAE. Arizona State Retirement System grew its holdings in Haemonetics by 1.2% during the 4th quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier's stock worth $1,160,000 after acquiring an additional 181 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after purchasing an additional 240 shares in the last quarter. HighTower Advisors LLC increased its holdings in Haemonetics by 7.8% in the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock valued at $262,000 after buying an additional 244 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new stake in Haemonetics during the fourth quarter valued at approximately $25,000. Finally, Xponance Inc. lifted its holdings in Haemonetics by 5.9% during the 4th quarter. Xponance Inc. now owns 7,246 shares of the medical instruments supplier's stock worth $566,000 after buying an additional 404 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Price Performance

Shares of HAE stock traded up $1.06 during midday trading on Tuesday, reaching $63.55. 58,947 shares of the company were exchanged, compared to its average volume of 688,492. The company's 50 day moving average price is $62.69 and its two-hundred day moving average price is $71.59. The company has a market cap of $3.19 billion, a P/E ratio of 24.88, a PEG ratio of 1.11 and a beta of 0.32. Haemonetics Co. has a 12 month low of $55.30 and a 12 month high of $97.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97.

Haemonetics (NYSE:HAE - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, sell-side analysts expect that Haemonetics Co. will post 4.55 earnings per share for the current year.

Analysts Set New Price Targets

HAE has been the topic of several research reports. Bank of America lowered Haemonetics from a "neutral" rating to an "underperform" rating and dropped their price target for the company from $95.00 to $68.00 in a research report on Friday, February 7th. Raymond James reissued a "strong-buy" rating and issued a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. Barrington Research dropped their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. StockNews.com raised shares of Haemonetics from a "hold" rating to a "buy" rating in a report on Monday. Finally, Needham & Company LLC dropped their price objective on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Haemonetics presently has a consensus rating of "Moderate Buy" and an average target price of $101.22.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.